Professor, Department of Radiology (Nuclear Medicine)
Professor, Department of Microbiology & Immunology
Sylvia and Robert S. Olnick Faculty Scholar in Cancer Research
Dadachova’s laboratory exists at the Albert Einstein College of Medicine since the
end of 2000. We are interested in targeted radionuclide therapy of cancer and
infectious diseases and radiation protection materials. Radionuclides emit particles
capable of destroying the cells. Monoclonal antibodies are perfect “vehicles” for
targeted delivery of radionuclides to the cancerous or microbial cells. Such modality
is called radioimmunotherapy (RIT). RIT is currently routinely used in the clinic for
treatment of some cancers and dozens of clinical trials are also being conducted
1. Novel treatments for metastatic melanoma. We are targeting melanin in tumors
with radiolabeled melanin-binding antibody as a basis of therapy for currently
incurable metastatic melanoma. Since mid-2001 when we started this work - the RIT of
melanoma with melanin-binding 6D2 mAb has made into the clinic and Phase I/II
clinical trial has been completed with the encouraging results and reported at
the 2011 meeting of the American Society for Clinical Oncology and published
in 2013. In the lab we are currently evaluating interaction of RIT with melanoma
stem cells in order to design more effective treatment protocols for the patients.
2. Radioimmunotherapy of HIV and fungal infections. RIT for infection is theoretically
useful for any microbe susceptible to radiation killing including bacteria, fungi, viruses
and parasites. One could anticipate that targeting microbes will be easier than targeting
neoplastic cells given the enormous antigenic differences between host and microbe.
Currently we are investigating the possibility of treating invasive fungal infections with
radiolabeled antibodies to universally shared fungal antigens to avoid the lengthy diagnosis
of the disease in immunocompromised patients. Bill and Melinda Gates Foundation
funding enabled us to study the interaction of anti-retroviral therapy (ART) with RIT
targeting HIV-infected human cells as a prelude for the clinical trial of RIT of HIV in
3. Radioimmunotherapy of cancers of viral origin. We have pioneered the use RIT for
targeting viral antigens in cancers of viral origin such as HPV-related cervical or head
and neck cancers and Hepatitis B-related hepatocellular carcinoma. The
fundamental novelty of this approach to treat cancer as an infectious disease is that
the viral antigens are very different from “self” human antigens thus providing
unmatched specificity of the treatment and simultaneously minimizing toxicity
to normal tissues. We are collaborating on this project with Dr. R. Phaeton,
a physician-scientist working in the field of gynecological oncology at the Hershey
Medical Center, Penn State University.
4. Melanin pigment as an energy transducer and radioprotector. We are investigating
melanin's energy transduction properties with one of the purposes of this work being
to create novel materials for internal and external radiation protection of patients undergoing
radiation therapy of cancer as well as in case of radiological accidents like "dirty bomb".
This project also involves expanding our observations on the fundamentally new role
which melanin can play in melanized microogranisms by converting the energy of ionizing
radiation into the chemical energy usable in a microbial cell life cycle - the process which we
called "radiosynthesis" by analogy with photosynthesis in green plants. Our first paper
on this subject appeared in PLOS ONE 2007 and caused enormous interest with more than 100,000 people
reading it just on the journal’s website
Our current research in this field is funded by the Defense Threat Reduction Agency.
5. Radioactive Listeria for treatment of pancreatic cancer. In collaboration with Dr. Claudia
Gravekamp from the M&I we created a radioactive Listeria monocytogenes bacteria which
can carry radionuclides into the tumors and destroy them by combined effect of reactive
oxygen species and radiation. Such therapy is very promising for highly aggressive cancers
with poor prognosis such as pancreatic cancer.
Shuryak I. and Dadachova E. New Approaches for Modeling Radiopharmaceutical Pharmacokinetics Using Continuous Distributions of Rates. J. Nucl. Med. Jul 23 2015 pii: jnumed.115.160515. [Epub ahead of print]
M. Shah, G. Garg and E. Dadachova Preclinical testing of radiopharmaceuticals for novel applications in HIV, bacterial and fungal infectious diseases. Q. J. Nucl. Med. Mol. Imaging Jul 22 2015 [Epub ahead of print]
M. Shah, R. Da Silva, C. Gravekamp, S. K. Libutti, T. Abraham, E. Dadachova Targeted radionuclide therapies for pancreatic cancer. Cancer Gene Ther. 22:375–379 (2015).
Dadachova E. and Berman JW. Non-invasive nuclear imaging for localization of viral reservoirs. Nature Meth. 12(5):399-400 (2015).
Prados-Rosales R, Toriola S, Nakouzi A, Chatterjee S, Stark R, Gerfen G, Tumpowsky P, Dadachova Å, Casadevall A. Structural characterization of melanin pigments from commercial preparations of the edible mushroom Auricularia auricula. J Agric Food Chem. Aug 5 2015 [Epub ahead of print]
R. Phaeton, J. Gutierrez, Z. Jiang, R.G. Karabakhtsian, J. Albanese, J. Sunkara, D. R. Fisher, G.L. Goldberg, and E. Dadachova Naïve and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer. Immunother. 7(6):631-40 (2015).
Rangel DE, Alder-Rangel A, Dadachova E, Finlay RD, Kupiec M, Dijksterhuis J, Braga GU, Corrochano LM, Hallsworth JE. Fungal stress biology: a preface to the Fungal Stress Responses special edition. Curr. Genet. 61(3):231-8 (2015).
Rangel DE, Alder-Rangel A, Dadachova E, Finlay RD, Dijksterhuis J, Braga GU, Corrochano LM, Hallsworth JE. The International Symposium on Fungal Stress: ISFUS. Curr Genet. 61(3):479-87 (2015).
Shuryak I, Bryan R, Broitman J, Marino S, Morgenstern A, Apostolidis C, Dadachova E. Effects of radiation type and delivery mode on a radioresistant eukaryote Cryptococcus neoformans. Nucl. Med. Biol. 42(6): 515-523 (2015).
C.S. Kang, Y. Chen, E. Dadachova, H.S. Chong Evaluation of benzyl-substituted DTPA analogues as decorporation agents of radionuclides. J. Radioanal. Nucl. Chem. 303(3): 2407-2411 (2015).
Dadachova E, Casadevall A. Radiolabeled antibodies for therapy of infectious diseases. Microbiol Spectr. 2(6):0023 (2014).
R.A. Bryan, Z. Jiang, T. Jandl, J.Strauss, W. Koba, C. Onyedika, A. Morgenstern, F. Bruchertseifer, R. S. Sellers, A. L. Epstein, E. Dadachova Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA. Expert Rev Anticancer Ther. 14(10):1243-9 (2014).
M. Sathekge, A. McFarren and E. Dadachova Role of nuclear medicine in neuroHIV - PET, SPECT and beyond. Nucl. Med. Commun. 35(8):792-6 (2014).
D. Tsukrov and E. Dadachova The potential of radioimmunotherapy as a new hope for HIV patients. Expert Rev. Clinical Immunol. 10(5):553-5 (2014).
Rivera J, Morgenstern A, Bruchertseifer F, Kearney JF, Turnbough CL Jr, Dadachova E, Casadevall A. Microbicidal Power of Alpha Radiation in Sterilizing Germinating Bacillus anthracis Spores. Antimicrob Agents Chemother. 58(3):1813-5 (2014).
Shuryak I, Bryan RA, Nosanchuk JD and Dadachova E Mathematical modeling predicts enhanced growth of X-ray irradiated pigmented fungi. PLoS One 9(1):e85561 (2014)
X.G. Wang, T. Jandl, E. Dadachova*, E. Revskaya* The effect of naïve and radiolabeled rhTRAIL on the cervical cancer xenografts in mice. Ther. Deliv. 5(2):1-9 (2014) (shared senior authorship)
P. Sukthankar, L.A. Avila, S. K. Whitaker, T. Iwamoto, A. Morgenstern, C. Apostolidis, K. Liu, R. P. Hanzlik, E. Dadachova, J. Tomich Branched Amphiphilic Peptide Capsules: Cellular Uptake and Retention of Encapsulated Solutes. Biochim Biophys Acta. 1838(9):2296-305 (2014)
S. Thompson, B. Ballard, Z. Jiang,E. Revskaya, N. Sisay, W.H. Miller, C. S. Cutler, E. Dadachova*, L.C. Francesconi* 166Ho- and 90Y-labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: comparison with 188Re radiolabel. Nucl. Med.Biol. 41(3):276-81 (2014) (shared senior authorship)
R.A. Bryan, Z. Jiang, A. Morgenstern, F. Bruchertseifer, A. Casadevall, E. Dadachova Radioimmunotherapy of Cryptococcus neoformans Spares Bystander Mammalian Cells. Future Microbiol. 8(9): 1-9 (2013).
T. Jandl, E. Revskaya, Z. Jiang, R.A. Bryan, A. Casadevall, E. Dadachova Unlabeled antibody to melanin contributes to the radioimmunotherapeutic efficacy of metastatic melanoma through complement-dependent cytotoxicity. Immunotherapy5(4): 1–7 (2013)
Harris M, Wang XG, Jiang Z, Phaeton R, Koba W, Goldberg GL, Casadevall A, Dadachova E. Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein. Br. J. Cancer 108(4):859-65 (2013)
W. Quispe-Tintaya, D. Chandra, A. Jahangir, M. Harris, A. Casadevall, E. Dadachova*, C. Gravekamp* A non-toxic radioactive Listeriaat is a highly effective therapy against metastatic pancreatic cancer. PNAS 110(21):8668-73 (2013) (*shared senior authorship)
M. Klein, M. Lotem, T. Peretz, S.T. Zwas, S. Mizrachi, Y. Liberman, R. Chisin, I. G. Ron, G. Iosilevsky, J.A. Kennedy, E. Revskaya, A. W. de Kater, E. Banaga, V. Klutzaritz, N. Friedmann, E. Galun, G. DeNardo, S. DeNardo, A. Casadevall, E. Dadachova, G. B. Thornton Safety and efficacy of 188-Rhenium-labeled antibody to melanin in patients with metastatic melanoma. J. Skin Cancer 2013:828329 (2013)
Jandl T, Revskaya E, Jiang Z, Harris M, Dorokhova O, Tsukrov D, Casadevall A, Dadachova E. Melanoma stem cells in experimental melanoma are killed by radio-immunotherapy. Nucl Med Biol. 40(2):177-81 (2013)
E. Revskaya, P.Chu, R.C. Howell, A.D. Schweitzer, R.A. Bryan, M. Harris, G. Gerfen, Z.Jiang, T. Jandl, K.Kim, L-M. Ting, R.S. Sellers, A. Casadevall, E. Dadachova Compton scattering by internal shields based on melanin-containing mushrooms provides protection of gastrointestinal tract from ionizing radiation. Cancer Biother. Radiopharm. 27(9):570-6 (2012).
Dufresne SF, Datta K, Li X, Dadachova E, Staab JF, Patterson TF, Feldmesser M, Marr KA. Detection of Urinary Excreted Fungal Galactomannan-like Antigens for Diagnosis of Invasive Aspergillosis. PLoS ONE 7(8):e42736 (2012).
R.A. Bryan, A.J. Guimaraes, S. Hopcraft, Z. Jiang, K. Bonilla, A. Morgenstern, F. Bruchertseifer, M. Del Poeta, A.Torosantucci, A. Cassone, J.D. Nosanchuk, A. Casadevall, and E. Dadachova Towards developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigens. Mycopathologia 73(5): 463-471 (2012)
Z. Jiang, R. A. Bryan, A. Morgenstern, F. Bruchertseifer, A. Casadevall and E. Dadachova Treatment of early and established Cryptococcus neoformans infection with radiolabeled antibodies in immunocompetent mice. Antimicrob. Agents Chemother. 56(1):552-4 (2012)
E. Dadachova, S.G. Kitchen, G. Bristol, G.C. Baldwin,E. Revskaya, C. Empig, G.B. Thornton, M. K. Gorny, S. Zolla-Pazner, A. Casadevall Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV1 mouse models as a reagent for HIV eradication. PLOS ONE 7(3): e31866 (2012).
S. Jaini and E. Dadachova 18FDG for Therapy of Metabolically Active Tumors. Sem. Nucl. Med. 42(3):185-9 (2012).
Nosanchuk JD, Dadachova E. Radioimmunotherapy of fungal diseases: the therapeutic potential of cytocidal radiation delivered by antibody targeting fungal cell surface antigens. Front Microbiol. 2:283 (2012)
Dadachova E, Casadevall A. Cryptococcus neoformans as a Model for Radio-immunotherapy of Infections. Interdiscip Perspect Infect Dis. 830286 (2011)
M. Harris, X-G. Wang, Z. Jiang, G. L. Goldberg, A. Casadevall, and E. Dadachova Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line. Head Neck Oncol. 3(1):9 (2011).
A. P. Johnson, L. M. Pratt, T. A. Vishnivetskaya, S. Pfiffner, R. A Bryan, E. Dadachova, L. Whyte, K. Radke, E. Chan, S. Tronick, G. Borgonie, R. L. Mancinelli, L. J. Rothschild, D. A. Rogoff, D. D. Horikawa, T. C. Onstott Extended Survival of Several Organisms and Amino Acids under Simulated Martian Surface Conditions. Icarus 211(2):1162-1178 (2011).
Turick CE, Ekechukwu AA, Milliken CE, Casadevall A, Dadachova E. Gamma radiation interacts with melanin to alter its oxidation-reduction potential and results in electric current production. Bioelectrochemistry. 82(1):69-73 (2011).
A. Khajo, R.A. Bryan, Y. Levitsky, M. Friedman, R. Burger, A. Casadevall, R. Magliozzo and E. Dadachova Protection of melanized Cryptococcus neoformans from lethal dose gamma irradiation involves changes in melanin's chemical structure and paramagnetism. PLOS ONE 6(9): e25092 (2011).
R. A. Bryan, Z. Jiang, M. Friedman, andE. DadachovaThe effects of gamma radiation, UV and visible light on ATP levels in yeast cells depend on cellular melanization. Fungal Biol. 115(10): 945-949 (2011).
B. Ballard, Z. Jiang, C. E. Soll, E. Revskaya, C. S. Cutler, E. Dadachova, L. C. FrancesconiIn vitro and in vivo evaluation of melanin-binding decapeptide 4B4 radiolabeled with 177Lu, 166Ho and 153Sm radiolanthanides for the purpose of targeted radionuclide therapy of melanoma. Cancer Biother. Radiopharm. 26(5): 547-556 (2011).
M. Paroder-Belenitsky, M. J. Maestas, O. Dohán, J. P. Nicola, A. Reyna-Neyra, A. Follenzi, E. Dadachova, S. Eskandari, L. M. Amzel, N. Carrasco Mechanism of Anion Selectivity and Stoichiometry of the Na+/I- Symporter (NIS). PNAS 108(44):17933-8 (2011)
C.A. Saylor, E. Dadachova, A. Casadevall Murine IgG1 and IgG3 isotype switch variants promote phagocytosis of Cryptococcus neoformans through different receptors. J. Immunol. 184:336-343 (2010).
R. Phaeton, X.G. Wang, M. H. Einstein, G. L. Goldberg, A. Casadevall, and E. Dadachova The influence of proteasome inhibitor MG132, external radiation and unlabeled antibody on the tumor uptake and biodistribution of 188Re-labeled anti-E6 C1P5 antibody in cervical cancer in mice. Cancer 116(S4):1067-1074 (2010).
Winterroth L, Rivera J, Nakouzi AS, Dadachova E, Casadevall A. A neutralizing monoclonal antibody to edema toxin and its effect on murine anthrax.Infect Immun. 78(6):2890-8 (2010).
A. D. Schweitzer, E. Revskaya, P. Chu, V. Pazo, M. Friedman, J.D. Nosanchuk, S. Cahill, S. Frases, A. Casadevall, and E. Dadachova Melanin-covered nanoparticles for protection of bone marrow during radiation therapy of cancer. Intern. J. Rad. Oncol. Biol. Physics. 78(5):1494-502 (2010).
R. A. Bryan, Z. Jiang, R. C. Howell, A. Morgenstern, F. Bruchertseifer, A. Casadevall, and E. Dadachova Radioimmunotherapy is More Effective than Antifungal Treatment in Experimental Cryptococcal Infection. J. Infect. Dis. 202(4): 633-7 (2010)
R. Phaeton, M. Harris, Z. Jiang, X-G. Wang, M. H. Einstein, G. L. Goldberg, A. Casadevall, and E. Dadachova Radioimmunotherapy with antibody to HPV-16 E6 oncoprotein is effective in experimental cervical tumor expressing low levels of E6. Cancer Biol. Ther. 10(10): 1041-1047 (2010).
E. Dadachova Therapy of cancer with alpha-emitters labeled peptides. Semin. Nucl. Med. 40:204-208 (2010).
More Information About Dr. Ekaterina Dadachova
Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.
Montefiore Medical Park
1695A Eastchester Road
Bronx, NY 10461
NBC News features Dr. Ekaterina Dadachova and her focus on radioimmunotherapy. Preclinical research shows it has the potential to eradicate HIV.
Science features new research by Drs. Claudia Gravekamp and Ekaterina Dadachova that uses radioactive bacteria to destroy metastatic pancreatic cancer.